Trivium Point Advisory’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-34,397
Closed -$996K 272
2025
Q4
$996K Sell
34,397
-3,172
-8% -$95.2K 0.1% 179
2025
Q3
$1.04M Buy
+37,569
New +$949K 0.11% 176

Other funds holding ARKG

Trivium Point Advisory's ARKG Position: Q1 2026 in Review

Trivium Point Advisory sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2026, closing a stake of 34,397 shares — an estimated $996K sold.

Trivium Point Advisory first reported a position in ARKG in Q3 2025 and held it in 2 quarters. The position peaked at $1.04M in Q3 2025. 218 funds tracked by Wall St. Rank hold ARKG as of Q1 2026.

  • Trivium Point Advisory reported no remaining ARK Genomic Revolution ETF position as of Q1 2026 after selling out during the quarter.
  • Trivium Point Advisory sold 34,397 ARK Genomic Revolution ETF shares in Q1 2026, an estimated $996K.
  • Trivium Point Advisory first reported a position in ARK Genomic Revolution ETF in Q3 2025 and held it in 2 quarters.
  • Trivium Point Advisory's ARK Genomic Revolution ETF position peaked at $1.04M in Q3 2025.
  • 218 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2026.

Based on Trivium Point Advisory's 13F filing for Q1 2026, filed 21 Apr 2026.